$SAVA cassavasciences.com/news-releases/…

Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders $SAVA -Shareholders of Record Received Warrants to Purchase Shares of Common Stock. -Warrants Trade on Nasdaq Under the Ticker “SAVAW”. -Warrant Holders Who Choose to Exercise During an Early Period

$SAVA #ENDALZ cassavasciences.com/node/16791/pdf

$SAVA cassavasciences.com/node/16806/pdf Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates -$121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional $21.8 Million Raised In 2024 From Exercise of Warrants. -A Total of Over 555

$SAVA Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference cassavasciences.com/news-releases/…

$SAVA cassavasciences.com/news-releases/… Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

$SAVA Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution cassavasciences.com

$SAVA Cassava Sciences Announces Expansion of Open-Label Extension Trials cassavasciences.com/node/17096/pdf

$SAVA Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET cassavasciences.com/news-releases/…

$SAVA Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson cassavasciences.com/node/17111/pdf

$SAVA cassavasciences.com/news-releases/… •$207.3 Million in Cash and Cash Equivalents at June 30, 2024. •Company in Advanced Discussions to Resolve SEC Investigation. $40 Million Estimated Loss Contingency Recorded in Q2 for Resolution. •Conference Webcast Scheduled for Today at

$SAVA Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference. cassavasciences.com/news-releases/…

$SAVA Cassava Sciences Names Rick Barry as Chief Executive Officer cassavasciences.com/node/17156/pdf

$SAVA Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials cassavasciences.com/news-releases/…

$SAVA Re-recording of disrupted 09/09/24 interview between CEO Rick Barry and HCW analyst. journey.ct.events/view/d574c934-…

$SAVA Cassava Sciences Resolves SEC Investigation cassavasciences.com/node/17196/pdf

$SAVA -Rethink Dosing Completed #ENDALZ #SIMUFILAM cassavasciences.com/static-files/d…

$SAVA Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer. cassavasciences.com/news-releases/…

$SAVA Cassava Sciences to Hold Corporate Update on November 25th Event Details:   Date:   Monday, November 25th   Time:   8:00 a.m. Eastern Time   Webcast:   lifescievents.com/event/cassava/